Michael W. Deininger
Impact in
- Hematology top 0.01%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Genetics top 0.01%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 429
- Chronic Myeloid Leukemia Treatments 381
- Acute Myeloid Leukemia Research 90
- Genetics 346
- Chronic Lymphocytic Leukemia Research 278
- Myeloproliferative Neoplasms: Diagnosis and Treatment 77
- Co-authors
- Brian J. Druker (123 shared papers)John M. Goldman (19 shared papers)Junia V. Melo (16 shared papers)Thomas O’Hare (86 shared papers)Christopher A. Eide (30 shared papers)Elisabeth Buchdunger (1 shared paper)Amie S. Corbin (21 shared papers)Jörge E. Cortes (50 shared papers)
- Journals
- Blood (182 papers)Leukemia (51 papers)Haematologica (14 papers)Journal of the National Comprehensive Cancer Network (11 papers)Cancer Research (10 papers)
- Partner nations
- United StatesGermanyUnited Kingdom
In The Last Decade
Michael W. Deininger
470 papers receiving 40.3k citations
Michael W. Deininger's Hit Papers
Peers
Comparison fields: 5 of 156
- Hematology 30.5k
- Genetics 21.2k
- Rheumatology 11.2k
- Oncology 5.4k
- Pathology and Forensic Medicine 2.4k
Countries citing papers authored by Michael W. Deininger
This map shows the geographic impact of Michael W. Deininger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael W. Deininger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael W. Deininger more than expected).
Fields of papers citing papers by Michael W. Deininger
This network shows the impact of papers produced by Michael W. Deininger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael W. Deininger. The network helps show where Michael W. Deininger may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael W. Deininger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 481 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia Hit paper breakdown → | 2006 | 2851 |
| 2 | A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis Hit paper breakdown → | 2012 | 1715 |
| 3 | European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 Hit paper breakdown → | 2013 | 1614 |
| 4 | The molecular biology of chronic myeloid leukemia Hit paper breakdown → | 2000 | 1318 |
| 5 | European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia Hit paper breakdown → | 2020 | 1080 |
| 6 | Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet Hit paper breakdown → | 2009 | 1050 |
| 7 | AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance Hit paper breakdown → | 2009 | 1045 |
| 8 | The development of imatinib as a therapeutic agent for chronic myeloid leukemia Hit paper breakdown → | 2004 | 1033 |
| 9 | Functional genomic landscape of acute myeloid leukaemia Hit paper breakdown → | 2018 | 997 |
| 10 | Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia Hit paper breakdown → | 2017 | 974 |
| 11 | A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias Hit paper breakdown → | 2013 | 940 |
| 12 | In vitro Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants Hit paper breakdown → | 2005 | 888 |
| 13 | Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance Hit paper breakdown → | 2000 | 657 |
| 14 | Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity Hit paper breakdown → | 2010 | 652 |
| 15 | Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias Hit paper breakdown → | 2012 | 622 |
| 16 | 1997 | 530 | |
| 17 | Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Hit paper breakdown → | 2007 | 527 |
| 18 | International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. Hit paper breakdown → | 2009 | 502 |
| 19 | Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial Hit paper breakdown → | 2018 | 454 |
| 20 | OncogenicCSF3RMutations in Chronic Neutrophilic Leukemia and Atypical CML Hit paper breakdown → | 2013 | 451 |
About Michael W. Deininger
Michael W. Deininger is a scholar working on Hematology, Genetics, Rheumatology, Public Health, Environmental and Occupational Health and Immunology, having authored 481 papers that have together received 41.5k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (381 papers), Chronic Lymphocytic Leukemia Research (278 papers), Eosinophilic Disorders and Syndromes (153 papers), Acute Myeloid Leukemia Research (90 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (77 papers), Acute Lymphoblastic Leukemia research (55 papers), Click Chemistry and Applications (29 papers) and Mast cells and histamine (29 papers). The work is most often cited by research in Hematology (30.5k citations), Genetics (21.2k citations), Rheumatology (11.2k citations), Oncology (5.4k citations) and Pathology and Forensic Medicine (2.4k citations). Michael W. Deininger has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Brian J. Druker, John M. Goldman, Junia V. Melo, Thomas O’Hare, Christopher A. Eide, Elisabeth Buchdunger, Amie S. Corbin, Jörge E. Cortes, Marc Loriaux and Andreas Hochhaus. Their work appears in journals such as Blood, Leukemia, Haematologica, Journal of the National Comprehensive Cancer Network and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.